Bolt Biotherapeutics (BOLT) vs BeyondSpring (BYSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BeyondSpring is the larger company by market cap ($13.7 million vs $12.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BOLT | BYSI |
|---|---|---|
| Share price | $4.91 | $0.33 |
| Market cap | $12.80M | $13.66M |
| 1-day change | -2.96% | -24.49% |
| YTD return | — | -79.75% |
| 1-year return | — | -82.77% |
| 5-year return | — | -97.70% |
| EPS (TTM) | $-14.00 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.70M | $0 |
| Revenue growth (YoY) | +0.07% | — |
| Net income (latest FY) | $-33.38M | $-1.01M |
| Operating margin | -469.30% | — |
| Net margin | -433.74% | — |
| 52-week high | $7.78 | $2.44 |
| 52-week low | $3.10 | $0.299 |
| Distance from 52-week high | -36.89% | -86.48% |
| Analyst consensus | none | — |
| Avg. price target upside | +490.63% | — |
| Average volume | 257.43K | 261.79K |
| Shares outstanding | 2.61M | 41.41M |
| Employees | 23 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bolt Biotherapeutics
BOLT stock →Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
About BeyondSpring
BYSI stock →BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
BOLT vs BYSI FAQ
Which is bigger, Bolt Biotherapeutics or BeyondSpring?
BeyondSpring (BYSI) is larger, with a market capitalization of $13.66M compared with $12.80M for Bolt Biotherapeutics (BOLT).
Are Bolt Biotherapeutics and BeyondSpring in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.